Skip to main content

Table 2 Associations between TDP-43 and Alzheimer’s disease pathologies using binary logistic regression (n = 929)

From: Dichotomous scoring of TDP-43 proteinopathy from specific brain regions in 27 academic research centers: associations with Alzheimer’s disease and cerebrovascular disease pathologies

Region OR (95% CI)a P-value
Diffuse plaques (moderate + frequent vs. no + sparse)
 Amygdala 3.34 (1.47–8.99) 0.0079
 Hippocampus 1.45 (0.81–2.71) 0.23
 EC/inferior TCTX 2.61 (1.20–6.53) 0.025
 Frontal neocortex 2.30 (0.63–14.93) 0.28
Neuritic plaques (moderate + frequent vs. no + sparse)
 Amygdala 2.84 (1.57–5.44) 9.1 × 10 − 4
 Hippocampus 2.56 (1.58–4.29) 2.2 × 10 − 4
 EC/inferior TCTX 4.04 (2.11–8.43) 6.6 × 10 − 5
 Frontal neocortex 1.88 (0.71–5.92) 0.23
Thal Aβ phase (phase 4 + 5 vs. phase 0 to 3)
 Amygdala 2.78 (1.56–5.21) 8.5 × 10 − 4
 Hippocampus 2.34 (1.44–3.93) 8.5 × 10 − 4
 EC/inferior TCTX 2.52 (1.41–4.77) 0.0029
 Frontal neocortex 1.42 (0.53–4.50) 0.51
Braak NFT stage (stage V + VI vs. stage 0 to IV)
 Amygdala 3.38 (1.99–5.95) 1.3 × 10 − 5
 Hippocampus 2.90 (1.86–4.63) 4.2 × 10 − 6
 EC/inferior TCTX 3.15 (1.86–5.53) 3.4 × 10 − 5
 Frontal neocortex 1.22 (0.52–3.06) 0.66
  1. aOdds ratios were adjusted for sex, age at death, APOE genotype, and the type of TDP-43 antibody
  2. OR odds ratio, CI confidence interval, EC entorhinal cortex, TCTX temporal cortex, NFT neurofibrillary tangle
  3. Bold p-value represents the statistical significance